Screener
Pfizer PFE Biopharma — Research and development expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pfizer in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Pfizer’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 7:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000078003-26-000054
| (MILLIONS) | Three Months Ended / March 29,2026 | Three Months Ended / March 30,2025 |
|---|---|---|
| Biopharma total revenues | $14,161 | $13,441 |
| Less: | ||
| Cost of sales | 3,034 | 2,314 |
| Selling, informational and administrative expenses | 2,131 | 2,186 |
| Research and development expenses | 2,137 | 1,941 |
| Acquired in-process research and development expenses | 137 | 9 |
| Other (income)/deductions––net | (116) | (78) |
| Biopharma earnings | $6,838 | $7,069 |
Item 1.
FAQ
- What is Pfizer's biopharma — research and development expenses?
- Pfizer (PFE) reported biopharma — research and development expenses of $2.14B in Q1 2026.
- How has Pfizer's biopharma — research and development expenses changed year-over-year?
- Pfizer's biopharma — research and development expenses increased by 10.1% year-over-year, from $1.94B to $2.14B.
- What is the long-term trend for Pfizer's biopharma — research and development expenses?
- Over 3 years (2022 to 2025), Pfizer's biopharma — research and development expenses has grown at a -3.8% compound annual growth rate (CAGR), from $10.32B to $9.18B.
- What does biopharma — research and development expenses mean?
- Expenditures dedicated to the discovery, clinical testing, and regulatory approval of new pharmaceutical products within the biopharma segment. This is a critical investment for long-term pipeline growth and future revenue sustainability.
Ask your AI about Pfizer's biopharma — research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude